(RTTNews) - Alterity Therapeutics Ltd. (ATHE) announced Wednesday positive interim data from the ATH434-202 open-label Phase 2 clinical trial in patients with multiple system atrophy or MSA. MSA is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and ...
标的公司:AlterityTherapeutics(ATE) AlterityTherapeutics(ATE)宣布,美国专利商标局(USPTO)授予一项新的物质成分专利。这项专利确保了一种新型ironchaperones的广泛垄断地位,这种技术能够在中枢神经系统中重新分配多余的铁。专利中所描述的结构骨架为小分子药物提供了可能跨越血脑屏障并直接攻击神经病理学来源的基础。单日+64...
(郑重声明:ACB News《澳华财经在线》对本文保留全部著作权限,任何形式转载请标注出处,违者必究。图片来自网络) Tags: 澳股异动股NXTATHALCFLTTLXISD # 今日复盘# 股市如棋局,开户先布局,随时把握投资机遇!